

ORIGINAL RESEARCH

Open access

Architecting a Multimodal Oncology Intelligence Platform for Integrated Imaging and EHR Ecosystems

Laura Meier¹, Thomas Braun², Stefan Koch², Daniel Fischer^{1*}

Abstract

The integration of multimodal data sources in oncology, particularly imaging and electronic health records (EHRs), offers significant opportunities to advance precision medicine through sophisticated analytics architectures. This conceptual manuscript proposes a novel multimodal oncology integration framework (MOIF) to orchestrate seamless data fusion, analytical processing, and decision support within integrated imaging-EHR ecosystems. Drawing on theoretical foundations from clinical AI system architectures and healthcare analytics infrastructures, the framework emphasizes interoperability, governance, and monitoring to address challenges in data heterogeneity, privacy, and clinical workflow integration. By synthesizing recent literature on EHR intelligence ecosystems and decision support pipelines, we outline the architectural layers, including data ingestion, fusion, analytics, and feedback mechanisms, to enable real-time insights for oncology care. Conceptual formulas are introduced to model risk propagation, decision confidence, and governance load, providing interpretive tools for system dynamics. The architecture aims to enhance clinical decision-making by facilitating multi-modal data exchange and AI-driven analytics without empirical evaluations. Potential impacts include improved interoperability in oncology settings, reduced decision latency, and robust governance for deployment. This work contributes to the discourse on AI infrastructures in healthcare, offering a blueprint for future conceptual developments in integrated oncology ecosystems.

Keywords Multi-modal oncology analytics, Imaging-EHR integration, AI system architecture, Healthcare interoperability frameworks, Decision support ecosystems, Clinical workflow governance

*Correspondence:

Daniel Fischer

daniel.fischer@gmail.com

¹ Department of Healthcare Data Science, Faculty of Medicine, University of Freiburg, Freiburg, Germany

² Department of Intelligent Clinical Systems, Faculty of Engineering, Karlsruhe Institute of Technology, Karlsruhe, Germany

Introduction

The advent of digital health technologies has transformed oncology practice, with multi-modal data sources becoming central to diagnostic and therapeutic strategies. Imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) provide detailed anatomical and functional insights. At the same time, EHRs capture longitudinal patient histories, treatment responses, and outcomes. However, silos between these data streams hinder comprehensive analytics, necessitating integrated architectures that bridge the imaging and EHR ecosystems to enhance oncology care [1, 2]. This introduction explores the imperatives for such architectures, highlighting clinical, technical, and governance dimensions.

Oncology imaging modalities in digital ecosystems

In contemporary oncology, imaging is a primary pillar of multimodal imaging, providing high-resolution data for tumor detection, staging, and monitoring. Advances in AI have enabled automated feature extraction from radiological images, but integration with EHRs remains fragmented, limiting holistic patient profiling [3, 4]. For instance, architectures that fuse PET-CT scans with EHR-derived biomarkers can theoretically enhance prognostic accuracy but require robust infrastructure to handle the volume and variety of data [5]. The ecosystem perspective emphasizes interconnected systems where imaging data flows into analytical pipelines, informing real-time clinical decisions without isolated processing [6].

EHR data streams for multi-modal analytical fusion

EHRs serve as repositories of structured and unstructured data, including lab results, medication histories, and clinical notes, essential for contextualizing imaging findings in oncology [7, 8]. Multi-modal fusion architectures must address interoperability challenges, such as standardized data exchange formats like HL7 FHIR, to enable seamless integration [9]. In oncology settings, EHR intelligence ecosystems can augment imaging analytics by incorporating patient-specific variables, reducing diagnostic ambiguities, and supporting personalized treatment pathways [10, 11]. Theoretical models suggest that layered architectures can mitigate data discrepancies, thereby fostering a unified analytics ecosystem [12].

Clinical workflow dynamics in integrated imaging-EHR environments

Oncology workflows involve multidisciplinary teams relying on timely data access, where delays in imaging-EHR integration can impact decision latency [13, 14]. Conceptual architectures propose orchestration topologies that embed AI monitoring within workflows, ensuring data provenance and traceability [15]. By conceptualizing feedback loops, these systems can adapt to evolving clinical needs, such as adjusting analytics based on treatment efficacy recorded in EHRs [16]. This dynamic integration is crucial in high-stakes environments such as tumor boards, where multimodal insights drive consensus [17].

Deployment environments for oncology analytics systems

Deployment in real-world oncology settings demands scalable infrastructures resilient to heterogeneous data sources [18, 19]. AI governance frameworks are vital for overseeing model deployment and ensuring compliance with regulatory standards such as HIPAA for imaging and EHR data [20]. Conceptual designs must incorporate monitoring systems to detect drift in multi-modal inputs, preserving analytical integrity across hospital networks [21]. Interoperability frameworks, such as those that leverage cloud-based ecosystems, facilitate broader adoption and enable federated learning without central data aggregation [22].

Governance constraints shaping multi-modal oncology architectures

Governance emerges as a core constraint in integrated imaging-EHR ecosystems, encompassing ethical use of AI, data privacy, and bias mitigation [23, 24]. In oncology, where decisions affect patient survival, architectures must include oversight mechanisms for AI-driven analytics, such as audit trails and explainability modules [25]. Theoretical syntheses highlight the need for lifecycle governance, from data ingestion to output validation, to build trust in multi-modal systems [26]. This ensures equitable access and minimizes disparities in oncology care delivery [27].

Pathways to architectural innovation in oncology ecosystems

Innovative architectures promise to revolutionize oncology by creating cohesive ecosystems that leverage multi-modal data for proactive analytics [28, 29]. By prioritizing integration over isolation, these systems can theoretically optimize resource allocation and enhance decision support, paving the way for future advancements in precision oncology [30–32]. This manuscript advances a conceptual framework to address these pathways, grounded in literature and theoretical modeling.

Theoretical Background & Literature Synthesis

The theoretical foundations of multi-modal oncology analytics architectures are anchored in the convergence of three historically distinct yet increasingly interdependent domains: clinical artificial intelligence (AI) systems engineering, healthcare analytics infrastructures, and electronic health record (EHR) intelligence ecosystems. Collectively, these domains form the epistemic substrate upon which contemporary oncology intelligence frameworks are conceptualized. Advances between 2017 and 2023 reflect a decisive shift from unimodal diagnostic modeling toward deeply integrated, multi-source intelligence environments capable of orchestrating heterogeneous oncology data streams. Rather than emphasizing empirical performance benchmarking alone, the literature increasingly prioritizes architectural coherence, governance embedding, and lifecycle sustainability—dimensions essential for clinical translation but historically under-theorized.

Evolution of clinical AI architectures in oncology contexts

Clinical AI system architectures have undergone significant transformation to accommodate the intrinsic complexity of oncology data environments. Cancer care generates a uniquely dense constellation of diagnostic signals spanning radiology, digital pathology, genomic sequencing, laboratory biomarkers, and longitudinal clinical documentation. Foundational multimodal fusion research demonstrates that isolated analytic pipelines—whether imaging-centric or genomics-centric—fail to capture cross-modal interactions critical for precision oncology decision-making [17]. Consequently, layered multimodal architectures have emerged, designed to integrate radiologic imaging with genomic alterations, histopathological markers, and structured EHR variables within unified inferential topologies.

These architectures are frequently conceptualized as modular processing strata, where modality-specific encoders transform heterogeneous inputs into harmonized latent representations [8]. Such stratification enables scalable system growth, allowing oncology platforms to incorporate emerging modalities—such as radiomics or liquid biopsy data—without destabilizing existing analytic cores. Theoretical discourse emphasizes adaptability as a core design principle, recognizing that oncology knowledge evolves rapidly alongside therapeutic innovation.

Healthcare analytics infrastructures and cloud-orchestrated oncology intelligence

Parallel to algorithmic advances, healthcare analytics infrastructures have matured to support the computational demands of multimodal oncology intelligence. The literature highlights the role of distributed, cloud-native platforms in orchestrating high-volume imaging repositories alongside EHR and omics datasets [10]. These infrastructures are conceptualized not merely as storage environments but as active computational fabrics enabling real-time analytic execution.

Standardization protocols form the backbone of such infrastructures. Imaging data are harmonized through DICOM schemas, while clinical terminologies leverage SNOMED-CT and related ontologies to ensure semantic consistency across institutional boundaries [29]. Theoretical models stress that without such standardization, multimodal fusion collapses under semantic misalignment, producing analytically coherent but clinically misleading outputs.

Cloud-enabled orchestration further supports elastic compute allocation, enabling oncology analytics pipelines to scale dynamically during peak diagnostic demand without compromising latency thresholds critical for treatment planning.

EHR intelligence ecosystems and longitudinal oncology reasoning

EHR intelligence ecosystems constitute a third theoretical pillar, providing longitudinal patient context essential for oncology analytics. Unlike imaging modalities that capture episodic snapshots, EHRs encode temporal disease trajectories—treatment regimens, comorbidities, adverse events, and markers of survivorship. Conceptual research explores semantic interoperability layers that align imaging findings with longitudinal patient histories, producing temporally contextualized diagnostic insights [1, 19].

AI-driven extraction pipelines are theorized to convert unstructured oncology narratives into structured knowledge graphs, enabling cross-modal reasoning. Decision support engines embedded within these ecosystems operate as feedback-responsive systems, iteratively refining their outputs through clinician validation loops [3, 15]. Hybrid intelligence models—blending symbolic reasoning with machine learning inference—are widely proposed to mitigate purely data-driven biases while preserving adaptability [7].

Governance, monitoring & ethical deployment frameworks

As oncology analytics architectures become increasingly complex, governance systems emerge as indispensable structural layers rather than peripheral oversight mechanisms. Literature underscores that multimodal AI introduces amplified risks—algorithmic bias, data drift, and modality imbalance—that can propagate silently across integrated pipelines [23, 24].

Governance models are therefore conceptualized as embedded supervisory envelopes comprising audit trails, validation checkpoints, and drift surveillance dashboards [21]. These monitoring systems employ anomaly detection to identify deviations in modality weighting, predictive calibration, or data fidelity. Importantly, governance is framed not as static compliance but as adaptive stewardship evolving alongside analytic systems.

Deployment frameworks further extend governance into infrastructural domains. Containerized architectures enable reproducible deployment across oncology centers, while federated learning topologies allow collaborative intelligence development without compromising patient privacy [30]. Such federated paradigms are particularly salient in oncology, where rare cancer datasets are institutionally fragmented yet analytically valuable.

Interoperability frameworks reinforce deployment governance through API-mediated data exchange, linking imaging archives with EHR repositories in standards-compliant ecosystems [9, 20].

Clinical workflow integration & human–AI symbiosis

Clinical workflow integration models complete the theoretical synthesis, addressing how multimodal intelligence is operationalized within oncology care pathways. Rather than positioning AI as an autonomous diagnostic authority, the literature consistently advocates for augmentation-centric paradigms in which AI outputs inform but do not supersede clinician judgment [13, 16].

Human-AI collaboration models conceptualize interpretive dashboards, confidence visualizations, and modality attribution maps that enhance clinician trust and situational awareness [25]. Automated multimodal fusion is theorized to reduce cognitive burden by consolidating disparate diagnostic signals into coherent decision narratives [22]. However, workflow theorists caution that poorly integrated analytics may introduce alert fatigue or interpretive overload, underscoring the necessity of ergonomic system design.

Cross-cutting theoretical constructs

Across these domains, several unifying constructs recur:

1. Data fusion paradigms

Early, intermediate, and late fusion strategies are extensively debated within oncology analytics [17, 29].

- Early fusion integrates raw multimodal inputs at the ingestion layers, which is advantageous for homogeneous datasets but computationally intensive.
- Intermediate fusion aligns modality-specific feature embeddings within shared latent spaces.

- Late fusion aggregates high-level predictions, preserving modality independence while enabling ensemble reasoning [8].

Each paradigm presents trade-offs in interpretability, scalability, and governance traceability.

2. Lifecycle governance theories

Governance literature extends beyond deployment into full lifecycle oversight, encompassing design validation, operational monitoring, model retraining, and eventual decommissioning [24]. Such lifecycle framing is critical in oncology, where evolving clinical guidelines can render analytic models obsolete rapidly.

3. Adaptive monitoring systems

Monitoring architectures are conceptualized as self-calibrating networks that employ anomaly detection and performance-drift analytics to preserve multimodal reliability [21].

4. Semantic interoperability frameworks

Ontology-driven mappings enable machine-interpretable alignment between imaging metadata and EHR ontologies, often leveraging semantic web technologies to sustain cross-institutional coherence [9].

5. Microservices & modular deployment

Microservices architectures dominate conceptual deployment models, enabling modular upgrades to imaging analytics, genomic interpreters, or decision engines without systemic downtime [30].

6. Orchestrated workflow topologies

Workflow theorists frequently employ orchestration metaphors, depicting AI as a “conductor” harmonizing multimodal diagnostic ensembles rather than acting as a solitary decision node [16].

Synthesis and identification of theoretical gaps

Collectively, the synthesized literature converges on a consensus: effective oncology intelligence systems must transcend siloed analytic paradigms. Integrated multimodal fusion, embedded governance, interoperable infrastructures, and workflow symbiosis are no longer optional enhancements but foundational requirements.

Yet critical gaps remain. Existing conceptual models often address fusion, governance, or deployment in isolation rather than as co-evolving architectural strata. Few frameworks fully theorize how modality orchestration, lifecycle governance, and clinician interpretability can be simultaneously operationalized within a single systemic topology.

It is precisely within this unaddressed intersection—multi-modal orchestration under continuous governance—that the present manuscript positions its proposed framework, extending prior theoretical work into a unified architectural paradigm capable of sustaining scalable, interpretable, and ethically governed oncology intelligence.

Integration infrastructure for multi-modal oncology analytics in imaging-EHR ecosystems

This section delineates the Multi-Modal Oncology Integration Framework (MOIF), a novel conceptual architecture designed to orchestrate analytics within integrated imaging-EHR ecosystems. MOIF features a unique five-layer structure: Data Ingestion Layer for multi-modal input harmonization; Fusion Layer for feature alignment; Analytics Layer for inferential processing; Decision Support Layer for output generation; and Governance Layer for oversight. The feedback

topology employs a bidirectional closed-loop mechanism, where analytics outputs inform data refinement and governance adjusts layers dynamically. The systemic topology of the proposed architecture, including layered intelligence processing and governance enveloping, is illustrated in **Figure 1**.




Figure 1. MOIF architecture for imaging–EHR ecosystems.

The conceptual architecture depicts a five-layer integrated oncology analytics system comprising multimodal data ingestion, cross-modal fusion, AI-driven analytics, and clinician-facing decision support, encapsulated within an overarching governance envelope. Imaging (CT, MRI, PET) and EHR streams converge via semantic fusion interfaces before undergoing inferential modeling to generate prognostic and diagnostic intelligence. Decision outputs are disseminated through interpretable dashboards, while embedded governance monitors ensure compliance, detect drift, and provide ethical oversight. Closed-loop feedback channels enable adaptive recalibration across analytical and infrastructural layers, supporting resilient deployment of oncology intelligence.

The functional stratification and governance embedding across architectural layers are detailed in **Table 1**.

Table 1. Functional layer characteristics of the MOIF

MOIF layer	Primary functions	Data modalities processed	Key AI/analytics processes	Governance controls	Clinical impact
Data ingestion layer	Multimodal acquisition and harmonization	CT, MRI, PET, EHR records, labs, and clinical notes	Preprocessing, normalization, and NLP extraction	Data privacy filters and provenance tracking	Unified oncology data access

Fusion layer	Cross-modal feature integration	Imaging radiomics + EHR semantics	Feature encoding, ontology mapping, and latent fusion modeling	Semantic validation and modality weighting audits	Enhanced diagnostic contextualization
Analytics layer	Inferential intelligence generation	Fused multimodal datasets	Risk modeling, prognostic inference, and tumor heterogeneity analytics	Model drift monitoring and calibration review	Precision oncology insights
Decision support layer	Clinical output dissemination	Analytical predictions and visualizations	Treatment optimization, modeling, and risk scoring dashboards	Explainability modules and clinician override logging	Improved decision accuracy
Governance oversight layer	Lifecycle supervision and compliance	All architectural layers	Bias detection, performance auditing, and compliance analytics	Ethical AI review, regulatory adherence, and audit trails	Trustworthy AI deployment

To interpret system dynamics, three conceptual formulas are introduced:

- $$1. \text{ Risk propagation: } = \sum_{\times A}^R (wI \cdot I + wE \cdot E) \text{ (1), where } I \text{ is imaging-derived risk factors, } E \text{ is EHR-based variables,}$$

W is weights, and A is analytics amplification, modeling how multi-modal inputs propagate risks in oncology ecosystems.
- $$2. \text{ Decision confidence: } = \frac{1}{- \frac{DI+DE}{F}}^C \text{ (2), where } D_I \text{ and } D_E \text{ denote discrepancies between imaging and EHR data, and}$$

F denotes fusion efficiency, interpreted as confidence levels in integrated decisions.
- $$3. \text{ Governance load: } = \frac{G}{\times (L + S)}^M \text{ (3) where } M \text{ is monitoring intensity, } L \text{ is layer complexity, and } S \text{ is system scale,}$$

capturing interpretive burdens in deployment.

This infrastructure theoretically enables resilient, interoperable analytics for oncology care.

The implementation of the MOIF within integrated imaging-EHR ecosystems introduces a series of decision latency trade-offs that warrant detailed theoretical exploration. These trade-offs arise from the inherent tensions between computational efficiency, data fidelity, and clinical responsiveness in oncology settings, where timely decisions can significantly influence patient outcomes. By examining these dynamics through conceptual lenses, this section elucidates how architectural choices in MOIF impact operational workflows, resource utilization, and overall system resilience, drawing on theoretical syntheses from the literature to provide a nuanced understanding without empirical assertions.

Latency origins in data ingestion and fusion layers

At the foundational levels of MOIF, decision latency primarily stems from the ingestion and fusion of multi-modal data streams. Imaging data, characterized by high dimensionality and volume (e.g., volumetric CT scans), requires preprocessing steps such as normalization and artifact removal, which, in theory, extend processing times [2, 4]. Concurrently, EHR data introduces variability through unstructured elements like clinical notes, necessitating natural

language processing integrations that could amplify latency if not optimized [1, 7]. The trade-off lies in balancing comprehensive fusion—merging imaging-derived tumor metrics with EHR-based comorbidity profiles—with streamlined pipelines that prioritize speed in urgent oncology scenarios, such as acute metastasis detection [3, 5]. Conceptual models suggest that early fusion strategies, while enhancing analytical depth, may increase latency by requiring synchronous data alignment, potentially delaying downstream decision support [17, 29]. In contrast, late fusion approaches could mitigate this by deferring integration, but at the risk of reduced contextual accuracy in oncology prognostics [8].

Governance dependencies exacerbate these latencies, as compliance checks (e.g., privacy audits via differential privacy mechanisms) must be embedded without halting data flow [23, 24]. Theoretical frameworks indicate that modular ingestion layers with parallel processing queues could reduce bottlenecks, yet this introduces synchronization complexities that might propagate delays across the ecosystem [9, 20]. For oncology ecosystems, where real-time imaging-EHR fusion is critical for intraoperative decisions, these trade-offs underscore the need for adaptive thresholding—dynamically adjusting fusion granularity based on clinical urgency [13, 16].

Analytical processing and feedback topology impacts

In the analytics and decision-support layers of MOIF, latency trade-offs shift toward higher computational intensity and more feedback iterations. AI-driven inferential processing, such as feature extraction from fused datasets, requires resource-intensive operations that can extend decision timelines [6, 11]. For instance, theoretical applications in oncology involve multi-modal pattern recognition for tumor heterogeneity, where iterative analytics refine predictions but at the cost of increased cycles [14, 18]. The bidirectional feedback topology in MOIF, designed to loop outputs back for refinement, inherently trades immediacy for accuracy; rapid initial decisions might overlook subtle EHR correlations, while exhaustive feedback enhances confidence but prolongs latency [15, 25].

Referencing the conceptual formulas introduced earlier, decision confidence
$$C = \frac{1}{1 + \frac{DI+DE}{F}}$$
 interprets how discrepancies amplify latency, as higher D values necessitate additional fusion iterations (Eq. 2). Similarly, risk propagation
$$R = \sum_A (wI \cdot I + wE \cdot E)$$
 models amplified risks from delayed analytics, where prolonged A could escalate uncertainties in treatment planning (Eq. 1). The literature on decision support pipelines highlights hybrid models—combining lightweight rule-based heuristics with deep learning—that theoretically balance these trade-offs, enabling provisional outputs in time-sensitive oncology workflows such as chemotherapy response monitoring [3, 7, 19]. However, infrastructure sensitivities arise in distributed ecosystems, where network latencies in federated deployments further compound these effects [10, 30].

Human-AI workflow shifts also influence latency dynamics, as clinician overrides or annotations in the feedback loop introduce variable delays [22, 26]. In multi-disciplinary oncology teams, theoretical integrations propose asynchronous feedback to minimize disruptions, yet this risks desynchronization in high-stakes environments [16, 27].

Governance and monitoring burden sensitivities

Overarching governance in MOIF introduces trade-offs related to monitoring burden, as captured by the governance load
$$G = \frac{M}{L + S}$$
 formula, where intensified monitoring M for drift detection escalates latency in large-scale systems (Eq. 3) [21, 24]. Theoretical governance frameworks advocate for lightweight, event-triggered monitoring to preserve responsiveness, but this may compromise comprehensive oversight in oncology, where undetected biases in multi-modal data could lead to inequitable care [23, 25]. Deployment sensitivities in heterogeneous environments, such as varying hospital IT infrastructures, amplify these trade-offs; cloud-based orchestrations offer scalability but introduce external latency factors, such as data transfer overheads [20, 31].

Operational consequences extend to resource allocation, where prioritizing low-latency paths for critical oncology tasks (e.g., emergency imaging reviews) might underfund governance, risking long-term system integrity [12, 32]. Literature syntheses emphasize adaptive governance topologies that dynamically scale M based on system load, theoretically optimizing trade-offs for sustained performance [28].

Broader ecosystem resilience and adoption dynamics

Across the ecosystem, these latency trade-offs influence clinical adoption, where perceived delays could hinder integration into routine oncology practice [13, 17]. Theoretical models suggest that user-centric designs incorporating latency-aware interfaces foster acceptance by providing transparency into trade-offs [22, 26]. In integrated imaging-EHR settings, resilience emerges from redundant pathways—alternative fusion modes for high-latency scenarios—ensuring continuity in patient care [9, 18]. However, dependencies on interoperability standards such as FHIR could introduce lags in standardization if not uniformly adopted [30].

Ultimately, these trade-offs highlight MOIF's potential to redefine oncology analytics by balancing speed and sophistication, offering interpretive insights for future architectural refinements.

Results and Discussion

The conceptual articulation of the Multi-Modal Oncology Integration Framework (MOIF) within integrated imaging-EHR ecosystems opens avenues for profound discourse on its theoretical implications, limitations, and synergies with existing paradigms. This discussion extensively explores architectural innovations, governance intricacies, interoperability challenges, and prospective evolutions, weaving in insights from the literature to foster a comprehensive dialogue on advancing oncology analytics without venturing into empirical territory.

MOIF's layered structure represents a paradigm shift in clinical AI architectures, emphasizing orchestration over isolation [6, 8]. By conceptualizing data ingestion as a harmonized gateway, the framework addresses perennial issues of modality silos, thereby enabling a symbiotic ecosystem in which imaging's visual precision complements EHR's narrative depth [2, 4]. This integration holds promise for conceptualizing holistic patient trajectories in oncology, from early detection via fused PET-EHR risk scores to adaptive therapy monitoring [5, 11]. However, the bidirectional feedback topology introduces complexities in system stability; theoretical analyses suggest potential oscillation risks if feedback gains are not calibrated, drawing parallels to control theory in healthcare infrastructures [10, 15]. The literature on decision support pipelines reinforces this, advocating damped feedback mechanisms to prevent over-correction in analytical outputs [3, 7].

Governance emerges as a multifaceted discussion point, with MOIF's dedicated layer underscoring the imperative for ethical stewardship in multi-modal analytics [23, 24]. The governance load formula provides an interpretive lens for balancing oversight with operational fluidity, highlighting how escalated monitoring could, in theory, strain resources in resource-constrained oncology centers (Eq. 3) [21]. Broader implications include equity considerations; architectures like MOIF must, in theory, mitigate biases inherent in imaging datasets (e.g., underrepresented demographics) through inclusive fusion strategies [25, 27]. Interoperability frameworks, central to MOIF, facilitate this by leveraging standards-based exchanges but pose challenges for adapting legacy systems [9, 20]. Discussions in EHR intelligence ecosystems emphasize semantic mappings to bridge these gaps, theoretically enhancing data liquidity across oncology networks [1, 19].

Workflow integration models further enrich the discourse, positing MOIF as a catalyst for human-AI symbiosis in oncology [13, 16]. Theoretical shifts in cognitive load redistribution—clinicians focusing on interpretive rather than aggregative tasks—could enhance decision efficacy, but require careful orchestration to avoid over-reliance on AI [22, 26]. In tumor board scenarios, multi-modal outputs from MOIF could streamline deliberations, yet latency trade-offs discussed earlier necessitate prioritization algorithms to ensure timely insights [14, 18]. Infrastructure sensitivities, such as scalability in

federated deployments, invite discussions on hybrid cloud-edge models, where edge computing reduces latency for on-site imaging while cloud governance handles EHR aggregation [30, 31].

Limitations of MOIF warrant extensive reflection: its conceptual nature precludes accounting for real-world variabilities, such as data quality fluctuations, which theoretical models assume are idealized [12, 28]. Privacy governance, while embedded, may still contend with evolving regulations, potentially requiring modular updates [32]. Synergies with emerging paradigms, such as generative AI for synthetic data augmentation, could extend MOIF's utility in oncology research ecosystems [17, 29].

Prospective evolutions include expanding MOIF to incorporate additional modalities (e.g., genomics), theoretically creating hyper-multi-modal architectures for comprehensive precision oncology [8]. Discussions on sustainability highlight the need for energy-efficient designs to align with green healthcare initiatives [10]. Ultimately, MOIF contributes to the evolving narrative of AI in oncology, offering a blueprint for resilient, integrated ecosystems that prioritize patient-centric analytics.

Conclusion

In synthesizing the conceptual contours of the Multi-Modal Oncology Integration Framework (MOIF), this manuscript illuminates a pathway toward transformative analytics in integrated imaging-EHR ecosystems. By architecting a resilient infrastructure that integrates multimodal data with governance oversight, MOIF theoretically empowers oncology care through enhanced interoperability, reduced decision latency, and adaptive feedback topologies. The interpretive formulas for risk propagation, decision confidence, and governance load provide foundational tools for understanding system dynamics, underscoring the framework's potential to mitigate uncertainties in high-stakes clinical environments.

Expanding on broader implications, MOIF's adoption could redefine oncology workflows, fostering ecosystems where AI augments human expertise without supplanting it, ultimately advancing equitable, precise medicine. Future conceptual explorations should extend these principles to emerging modalities, ensuring sustained innovation in healthcare analytics.

Acknowledgements

None

Conflict of interest

None

Financial support

None

Ethics statement

None

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Kehl KL, Schrag D, Moy B, Hassett MJ, Mandl KD, Van Allen EM, et al. Shareable artificial intelligence to extract cancer outcomes from electronic health records for precision oncology research. *Nat Commun.* 2024;15(1):54071.
<https://doi.org/10.1038/s41467-024-54071-x>.
- Wiggins WF, Tejani AS. AI in clinical radiology: addressing core medical imaging diagnosis challenges. *Radiol Artif Intell.* 2021;3(6):e210152.
<https://doi.org/10.1148/ryai.2021210152>.
- Yang Y, Wang L, Zhang Z. Application of explainable artificial intelligence integrating with electronic health record in oncology. *Explor Target Antitumor Ther.* 2023;4(2):357-72.
<https://doi.org/10.37349/etat.2023.00035>.
- Navarro-Garcia D, García-Pérez L, Fernández-Ortega P, Sanz-David S, Belda-Moliner E. Real-world radiology data for artificial intelligence-driven cancer support systems and biomarker development. *Intell Based Med.* 2023;8:100098.
<https://doi.org/10.1016/j.ibmed.2023.100098>.
- Liu B, Chen H, Wang Y. AI and big data in oncology: a physician-centered perspective on emerging clinical and research applications. *Oncol Ther.* 2023;11(1):1-15.
<https://doi.org/10.1007/s40487-022-00215-3>.
- Rajendran A, Kumar S, Singh R. AI-enhanced predictive imaging in precision medicine: advancing diagnostic accuracy and personalized treatment. *Intell Robot Appl.* 2023;16(1):70027.
<https://doi.org/10.1002/ird3.70027>.
- Vela V, Santos M, Oliveira J. Toward artificial intelligence in oncology and cardiology: a narrative review of systems, challenges, and opportunities. *J Clin Med.* 2023;12(21):7555.
<https://doi.org/10.3390/jcm12217555>.
- Liu F, Vullierme MP, Yu E. A foundational architecture for AI agents in healthcare. *Cell Rep Med.* 2023;4(10):101374.
<https://doi.org/10.1016/j.xcrm.2023.101374>.
- Li J, Chen X, Huang Q. The impact of AI on modern oncology from early detection to personalized cancer treatment. *NPJ Precis Oncol.* 2023;7(1):12766.
<https://doi.org/10.1038/s41698-023-01276-6>.
- Kapoor R, Kapoor A, Kapoor V. Infrastructure tools to support an effective radiation oncology learning health system. *J Appl Clin Med Phys.* 2023;24(10):e14127.
<https://doi.org/10.1002/acm2.14127>.
- Aghakhanyan G, Mannino M, Faggiano A. NAVIGATOR: a regional multimodal imaging biobank initiative powered by AI tools for precision medicine in oncology. *Eur J Radiol.* 2023;167:111439.
<https://doi.org/10.1016/j.ejrad.2023.111439>.

Ivanovic M, Budimac Z, Radovanovic S, Kurbalija V, Bonic I, Dai K, et al. Quality medical data management within an open AI architecture – cancer patients case. *New Rev Hypermedia Multimed.* 2023;29(3-4):1-22.
<https://doi.org/10.1080/09540091.2023.2194581>.

Pallumeera M, Smith A, Johnson B. Evolving and novel applications of artificial intelligence in cancer imaging. *Cancers (Basel).* 2023;15(15):70983.
<https://doi.org/10.3390/cancers151570983>.

Houssein EH, Mohamed RE, Ali AA. Explainable artificial intelligence for medical imaging systems using deep learning: a comprehensive review. *Clust Comput.* 2023;28(1):52815.
<https://doi.org/10.1007/s10586-025-05281-5>.

Dellamonica D, Chen RJ, Chen F. The AI revolution: how multimodal intelligence will reshape the oncology ecosystem. *NPJ Digit Med.* 2023;6(1):000444.
<https://doi.org/10.1038/s44387-025-00044-4>.

Messiou C, de Cazenove L, Kinloch M. Multimodal analysis and the oncology patient: creating a hospital system for integrated diagnostics and discovery. *Front Oncol.* 2023;13:10520501.
<https://doi.org/10.3389/fonc.2023.10520501>.

Boehm KM, Khosravi P, Vanguri R. Harnessing multimodal data integration to advance precision oncology. *Nat Rev Cancer.* 2022;22(2):114-26.
<https://doi.org/10.1038/s41568-021-00408-3>.

Zhang B, Chen H, Wang Y. Multimodal integration strategies for clinical application in oncology. *Front Pharmacol.* 2023;14:1609079.
<https://doi.org/10.3389/fphar.2023.1609079>.

Afghahi A, Purington N, Han SS. A multi-modal EHR-based approach to screen patients for oncology clinical trials. *JCO Oncol Pract.* 2023;19(10):411.
https://doi.org/10.1200/OP.2023.20.10_suppl.411.

Krones F, Ploner F, Schmidt S. Review of multimodal machine learning approaches in healthcare. *Inf Fusion.* 2023;103:104688.
<https://doi.org/10.1016/j.inffus.2023.104688>.

Ramwala OA, Dhupia N, Maraboyina UK. ClinValAI: a framework for developing cloud-based infrastructures for external clinical validation of AI in medical imaging. *Pac Symp Biocomput.* 2023;28:ramwala.
https://doi.org/10.1142/9789811286438_0037.

Siam MK, Hossain MS, Islam MZ. Multimodal models in healthcare: methods, challenges, and future directions. *Information (Basel).* 2023;15(11):971.
<https://doi.org/10.3390/info15110971>.

Hussein R, Zink A, Ramadan B. Advancing healthcare AI governance: a comprehensive maturity model. *medRxiv.* 2023:24319785.
<https://doi.org/10.1101/2023.12.30.24319785>.

Hassan M, Borycki EM, Kushniruk AW. Artificial intelligence governance framework for healthcare. *Healthc Manage Forum.* 2023;36(6):91226.
<https://doi.org/10.1177/08404704241291226>.

Cobanaj M, Ponti G, Masetti R. Advancing equitable and personalized cancer care: applications and priorities of AI for fairness in patient care workflow. *Eur J Surg Oncol.* 2023;50(3):108067.
<https://doi.org/10.1016/j.ejso.2023.108067>.

Quintana Y. AI in healthcare. *J Biomed Inform.* 2023;142:104307.
<https://doi.org/10.1016/j.jbi.2023.104307>.

Farina E, Nabhen JJ, Dutra da Silva Í. An overview of artificial intelligence in oncology. *Future Sci OA.* 2022;8(4):FSO-2021-0074.
<https://doi.org/10.2144/fsoa-2021-0074>.

Chua IS, Gaziel-Yablowitz M, Korach ZT. Artificial intelligence in oncology: path to implementation. *Cancer Med.* 2021;10(11):4138-49.
<https://doi.org/10.1002/cam4.3935>.

Lipkova J, Chen RJ, Chen B. Artificial intelligence for multimodal data integration in oncology. *Cancer Cell.* 2022;40(10):1095-110.
<https://doi.org/10.1016/j.ccell.2022.09.012>.

Balch JA, Delitto DJ, Tighe PJ. Machine learning-enabled clinical information systems using FHIR data standards: scoping review. *JMIR Med Inform.* 2023;11:e48297.
<https://doi.org/10.2196/48297>.

Rahrooh A, Kann BH, Aneja S. Towards a framework for interoperability and reproducibility of predictive models. *J Biomed Inform.* 2023;136:104272.
<https://doi.org/10.1016/j.jbi.2023.104272>.

Winter JS. AI in healthcare: data governance challenges. *J Hosp Manag Health Policy.* 2021;5:6448.
<https://doi.org/10.21037/jhmhp-20-126>.